This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma
Tumour Biol. 2017 Jun;39(6) :1010428317700410
PMID: 28635398 URL: https://www.ncbi.nlm.nih.gov/pubmed/28635398
AbstractGlutathione peroxidase 2 has important role of tumor progression in lots of carcinomas, yet little is known about the prognosis of glutathione peroxidase 2 in hepatocellular carcinoma. Glutathione peroxidase 2 expression was assessed by immunohistochemistry in hepatocellular carcinoma tissues. The association between glutathione peroxidase 2 expression with clinicopathological/prognostic value was examined. Glutathione peroxidase 2 overexpression was correlated with alpha-fetoprotein level, larger tumor, BCLC stage, and tumor recurrence. Kaplan-Meier analysis showed that glutathione peroxidase 2 was an independent predictor for overall survival and time to recurrence. glutathione peroxidase 2 overexpression was correlated with poor prognosis in patient subgroups stratified by tumor size, differentiation, tumor-node-metastasis, and BCLC stage. Moreover, stratified analysis showed that tumor-node-metastasis stage-I patients with high glutathione peroxidase 2 expression had poor prognosis than those with low glutathione peroxidase 2 expression. Additionally, combination of glutathione peroxidase 2 and serum alpha-fetoprotein was correlated with prognosis in hepatocellular carcinoma. In conclusion, glutathione peroxidase 2 overexpression contributes to poor prognosis of hepatocellular carcinoma patients and helps to identify the high-risk hepatocellular carcinoma patients.
Notes1423-0380 Liu, Ting Kan, Xue-Feng Ma, Charlie Chen, Li-Li Cheng, Tian-Tian Zou, Zhen-Wei Li, Yong Cao, Feng-Jun Zhang, Wen-Jie Yao, Jing Li, Pin-Dong Journal Article United States Tumour Biol. 2017 Jun;39(6):1010428317700410. doi: 10.1177/1010428317700410.